Page last updated: 2024-08-24

zanamivir and Infections, Orthomyxoviridae

zanamivir has been researched along with Infections, Orthomyxoviridae in 68 studies

Research

Studies (68)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	8 (11.76)	18.2507
2000's	22 (32.35)	29.6817
2010's	34 (50.00)	24.3611
2020's	4 (5.88)	2.80

Authors

Authors	Studies
Beresford, A; Bethell, R; Cherry, PC; Cobley, KN; Fenton, RJ; Green, D; Howes, PD; Madar, S; Merritt, A; Morley, PJ; Pateman, T; Scicinski, J; Smith, PW; Sollis, SL; Starkey, ID; Taylor, N; Weston, H; Whittington, A; Wyatt, P	1
Ananth, SL; Babu, YS; Bantia, S; Chand, P; Dehghani, A; El-Kattan, Y; Elliott, AJ; Horn, LL; Hutchison, TL; Kotian, P; Laver, GW; Lin, TH; Montgomery, JA; Parker, CD	1
Arai, M; Honda, T; Masuda, T; Yamashita, M; Yoshida, S	1
Arai, M; Honda, T; Masuda, T; Ohno, A; Shibuya, S; Tomozawa, T; Yamashita, M; Yoshida, S	1
Cameron, R; Fenton, RJ; Gower, D; Hamilton, S; Jin, B; Krippner, GY; Luttick, A; MacDonald, SJ; Mason, AM; McConnell, D; Nguyen, V; Tucker, SP; Watson, KG; Wu, WY	1
Barr, IG; Holien, JK; Hurt, AC	1
Kakuta, M; Kubo, S; Tokumitsu, A; Tomozawa, T; Yamashita, M	2
Cheng, TJ; Cheng, YS; Fang, JM; Jan, JT; Liu, KC; Wang, SY; Wong, CH; Yang, ST	1
Chen, CA; Chen, CL; Cheng, TJ; Cheng, YS; Fang, JM; Hsieh, WC; Hu, OY; Huang, PW; Jan, JT; Lin, WH; Shie, JJ; Tarbet, EB; Wang, SY; Weinheimer, S; Wong, CH	1
Hao, C; Jiang, T; Wang, W; Yin, R; Yu, R; Zhang, L; Zhang, M	1
Cao, R; Dai, Q; Guo, X; Li, W; Li, X; Li, Y; Xia, Q; Xu, K; Yan, Y; Yang, J; Yang, K; Zhao, L; Zhong, W; Zou, G	1
Abed, Y; Baz, M; Boivin, G; Checkmahomed, L; Padey, B; Pizzorno, A; Rosa-Calatrava, M; Terrier, O	1
Haymour, HS; Liu, X; Low, PS; Srinivasarao, M; Wang, Y; Xu, LC; Zhang, B; Zhang, F	1
Lee, YG; Liu, X; Low, PS; Luo, W; Shahriar, I; Srinivasarao, M; Zhang, B	1
Cho, J; Jang, EY; Kang, C; Kim, K; Lee, CH; Lee, JY; Lee, MS; Yi, H	1
Hasegawa, H; Ito, M; Kawaoka, Y; Kiso, M; Lopes, TJS; Nakajima, N; Neumann, G; Yamashita, M; Yamayoshi, S	1
Hoshino, K; Kubo, S; Tomozawa, T; Yamashita, M	1
Devalapally, H; Holmes, EH; Li, L; Ostrander, GK; Perdue, ML	1
Belser, JA; Chen, J; Klibanov, AM; Tumpey, TM; Weight, AK	1
Abed, Y; Boivin, G; Pizzorno, A; Rhéaume, C	1
Crawford, S; Hamilton, S; Hurst, BL; Luttick, A; Ng, WC; Pryor, M; Smee, DF; Tarbet, EB; Tucker, SP; Vollmer, AH	1
Cheng, CK; Fang, JM; Shie, JJ; Tsai, CH	1
Bahl, J; Baranovich, T; Culhane, M; Darnell, D; Govorkova, EA; Kaplan, BS; Lowe, JF; Marathe, BM; Stigger-Rosser, E; Webby, RJ	1
Hurt, AC; Margo, K; Morton, DA; Mosse, J; Oh, DY; Panozzo, J; Piedrafita, D	1
Clement, B; Hoffmann, A; Kotthaus, J; Müller-Fielitz, H; Raasch, W; Riebling, L; Schade, D; Schmidtke, M	1
Graf, C; Graf, P; Grassauer, A; Kirchoff, N; Koller, C; König-Schuster, M; Morokutti-Kurz, M; Nakowitsch, S; Prieschl-Grassauer, E; Reutterer, B; Seifert, JM; Unger, H	1
Abed, Y; Ann, J; Beaulieu, E; Boivin, G; Bouhy, X; Carbonneau, J; Dubé, K; Hamelin, ME; Joly, MH; Mallett, C	1
Dor, D; Handel, A; Pawelek, KA; Salmeron, C	1
Gabor, KA; Goody, MF; Jurcyzszak, D; Kim, CH; Longfellow, JR; Millard, PJ; Sullivan, C	1
Farrukee, R; Hurt, AC; Mosse, J; Oh, DY; Panozzo, J; Piedrafita, D; Vitesnik, S	1
Farrar, J; Simmons, C	1
Barr, IG; Holien, JK; Hurt, AC; Kelso, A; Parker, M	1
Hacker, J	1
Kawaoka, Y; Kiso, M; Kubo, S; Le, QM; Nidom, CA; Ozawa, M; Yamashita, M	1
Govorkova, EA; Ilyushina, NA; Rehg, JE; Seiler, JP; Webster, RG	1
Barr, IG; Hurt, AC; Lowther, S; Middleton, D	1
DeLiberto, T; DuBois, RM; Govorkova, EA; Gramer, MR; Krauss, S; Negovetich, NJ; Senne, DA; Stallknecht, DE; Stoner, TD; Swafford, S; Webster, RG	1
Albrecht, RA; García-Sastre, A; Kaminski, M; Kochs, G; Medina, RA; Palese, P; Philipp, J; Rubbenstroth, D; Schwalm, F; Seibert, CW; Staeheli, P; Stertz, S	1
Horimoto, T; Imai, H; Kakugawa, S; Kawaoka, Y; Kiso, M; Le, MT; Noda, T; Ozawa, M; Takahashi, K	1
Bauer, K; Dahse, HM; Dürrwald, R; Pfarr, K; Schlegel, M; Schmidtke, M; Topf, D; Wiesener, N; Wutzler, P	1
Abed, Y; Beaulieu, E; Boivin, G; Bouhy, X; Mallett, C; Pizzorno, A; Russell, R	1
Feng, E; Hilgenfeld, R; Jiang, H; Li, J; Liu, H; Wang, J; Ye, D; Zhang, D; Zhao, F; Zheng, M	1
Fukushi, M; Kubo, S; Kudo, K; Miyoshi-Akiyama, T; Yamamoto, K; Yamashita, M	1
Barbas, CF; Carrillo, N; Crowe, JE; Hayakawa, M; Thornburg, NJ; Toda, N	1
Chen, J; Haldar, J; Klibanov, AM; Lee, CM; Wang, L; Weight, AK	1
Kaminski, MM; Ohnemus, A; Rubbenstroth, D; Staeheli, P	1
Sauerbrei, A; Ulbricht, A; Wutzler, P	1
Blanco, J; Curtis, S; Ottolini, M; Peterson, L; Porter, D; Prince, G	1
Elias, S; Fenton, R; Herlocher, ML; Klimov, A; Monto, AS; Ohmit, SE; Truscon, R	1
Arai, M; Honda, T; Kaneko, S; Masuda, T; Yamashita, M; Yoshida, S	1
Härtl, A; Sauerbrei, A; Stelzner, A; Wutzler, P	1
Cameron, R; Chalmers, DK; Demaine, DA; Fenton, RJ; Gower, D; Hamblin, JN; Hamilton, S; Hart, GJ; Inglis, GG; Jin, B; Jones, HT; Macdonald, SJ; Mason, AM; McConnell, DB; Nguyen, V; Owens, IJ; Parry, N; Reece, PA; Shanahan, SE; Smith, D; Tucker, SP; Watson, KG; Wu, WY	1
Cameron, R; Demaine, DA; Fenton, RJ; Foster, G; Gower, D; Hamblin, JN; Hamilton, S; Hart, GJ; Hill, AP; Inglis, GG; Jin, B; Jones, HT; Macdonald, SJ; McConnell, DB; McKimm-Breschkin, J; Mills, G; Nguyen, V; Owens, IJ; Parry, N; Shanahan, SE; Smith, D; Tucker, SP; Watson, KG; Wu, WY	1
Babu, YS; Bantia, S; Chand, P; El-Kattan, Y; Kotian, PL; Lin, TH	1
Govorkova, EA; Monto, AS; Webster, RG; Yen, HL	1
Govorkova, EA; Herlocher, LM; Hoffmann, E; Matrosovich, MN; Monto, AS; Webster, RG; Yen, HL	1
Reece, PA	1
Dempsey, MH; Penn, CR; Ryan, DM; Ticehurst, J	1
Dempsey, MH; Ryan, DM; Ticehurst, J	1
Bischofberger, N; Chen, MS; Escarpe, PA; Huffman, JH; Jakeman, KJ; Kim, CU; Lacy, SA; Lew, W; Li, W; Mendel, DB; Merson, J; Sidwell, RW; Sweet, C; Tai, CY; Williams, MA; Zhang, L	1
Blick, TJ; Fenton, RJ; McDonald, M; McKimm-Breschkin, JL; Morley, PJ; Owens, IJ; Sahasrabudhe, A	1
Bethell, RC; Brenner, MK; Gubareva, LV; Matrosovich, MN; Webster, RG	1
Crossman, L; Fenton, RJ; Gower, D; Morley, PJ; Owens, IJ; Parry, S; Wong, T	1
McCauley, J	1
Ananth, SL; Andries, K; Babu, YS; Bantia, S; Chand, P; Dehghani, A; El-Kattan, Y; Horn, LL; Hutchison, TL; Kellog, DL; Kotian, PL; Lin, T; Montgomery, JA; Parker, CD	1
Fenton, RJ; Goloubeva, O; Leneva, IA; Tisdale, M; Webster, RG	1
Bush, K; Goloubeva, OG; Govorkova, EA; Leneva, IA; Webster, RG	1

Reviews

3 review(s) available for zanamivir and Infections, Orthomyxoviridae

Article	Year
From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs? Future medicinal chemistry, 2014, Volume: 6, Issue:7 Topics: Animals; Antiviral Agents; Drug Design; Enzyme Inhibitors; Humans; Influenza, Human; Molecular Targeted Therapy; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Zanamivir	2014
Recent advances in neuraminidase inhibitor development as anti-influenza drugs. ChemMedChem, 2012, Volume: 7, Issue:9 Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Benzoic Acid; Cyclopentanes; Drug Design; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Models, Molecular; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Zanamivir	2012
Neuraminidase inhibitor resistance in influenza viruses. Journal of medical virology, 2007, Volume: 79, Issue:10 Topics: Acids, Carbocyclic; Adult; Animals; Antiviral Agents; Catalytic Domain; Child; Clinical Trials as Topic; Cyclopentanes; Drug Administration Schedule; Enzyme Inhibitors; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Seasons; Sentinel Surveillance; Viral Proteins; Virulence; Zanamivir	2007

Other Studies

65 other study(ies) available for zanamivir and Infections, Orthomyxoviridae

Article	Year
Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides. Journal of medicinal chemistry, 1998, Mar-12, Volume: 41, Issue:6 Topics: Administration, Intranasal; Animals; Antiviral Agents; Enzyme Inhibitors; Guanidines; Influenza A virus; Influenza B virus; Injections, Intraperitoneal; Mice; Neuraminidase; Orthomyxoviridae Infections; Pyrans; Sialic Acids; Structure-Activity Relationship; Zanamivir	1998
BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. Journal of medicinal chemistry, 2000, Sep-21, Volume: 43, Issue:19 Topics: Acids, Carbocyclic; Administration, Oral; Animals; Antiviral Agents; Catalytic Domain; Crystallography, X-Ray; Cyclopentanes; Drug Design; Enzyme Inhibitors; Guanidines; Influenza A virus; Influenza B virus; Mice; Models, Molecular; Neuraminidase; Orthomyxoviridae Infections; Protein Binding; Stereoisomerism; Structure-Activity Relationship	2000
Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives. Bioorganic & medicinal chemistry letters, 2002, Aug-05, Volume: 12, Issue:15 Topics: Animals; Antiviral Agents; Enzyme Inhibitors; Glutamic Acid; Glyceryl Ethers; Guanidine; Guanidines; Influenza A virus; Inhibitory Concentration 50; Mice; N-Acetylneuraminic Acid; Neuraminidase; Orthomyxoviridae Infections; Pyrans; Sialic Acids; Structure-Activity Relationship; Viral Plaque Assay; Zanamivir	2002
Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir. Bioorganic & medicinal chemistry letters, 2003, Feb-24, Volume: 13, Issue:4 Topics: Administration, Oral; Animals; Antiviral Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Evaluation, Preclinical; Enzyme Inhibitors; Ethers; Guanidines; Influenza A virus; Inhibitory Concentration 50; Mice; Models, Molecular; Molecular Conformation; Neuraminidase; Orthomyxoviridae Infections; Pyrans; Sialic Acids; Structure-Activity Relationship; Zanamivir	2003
Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase. Bioorganic & medicinal chemistry letters, 2004, Mar-22, Volume: 14, Issue:6 Topics: Animals; Antiviral Agents; Enzyme Inhibitors; Guanidines; Influenza A virus; Mice; Neuraminidase; Orthomyxoviridae Infections; Pyrans; Sialic Acids; Zanamivir	2004
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:10 Topics: Animals; Antiviral Agents; Cell Line; Dogs; Influenza A Virus, H5N1 Subtype; Mutagenesis, Site-Directed; Mutation; Neuraminidase; Orthomyxoviridae Infections; Reverse Transcriptase Polymerase Chain Reaction	2009
Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:3 Topics: Animals; Antiviral Agents; Disease Models, Animal; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Prodrugs; Treatment Outcome; Zanamivir	2010
Enhanced anti-influenza agents conjugated with anti-inflammatory activity. Journal of medicinal chemistry, 2012, Oct-11, Volume: 55, Issue:19 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Caffeic Acids; Cell Line; Dogs; Female; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Interferon-gamma; Interleukin-6; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tumor Necrosis Factor-alpha; Zanamivir	2012
Development of oseltamivir phosphonate congeners as anti-influenza agents. Journal of medicinal chemistry, 2012, Oct-25, Volume: 55, Issue:20 Topics: Acetamides; Administration, Oral; Alphainfluenzavirus; Animals; Antiviral Agents; Betainfluenzavirus; Biological Availability; Blood Proteins; Cyclohexenes; Cytopathogenic Effect, Viral; Dogs; Drug Resistance, Viral; Drug Stability; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Madin Darby Canine Kidney Cells; Male; Mice; Mice, Inbred BALB C; Microsomes, Liver; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Phosphorous Acids; Protein Binding; Rats; Structure-Activity Relationship	2012
Boronic Acid Modifications Enhance the Anti-Influenza A Virus Activities of Novel Quindoline Derivatives. Journal of medicinal chemistry, 2017, 04-13, Volume: 60, Issue:7 Topics: Alkaloids; Animals; Antiviral Agents; Boronic Acids; Cell Line; Female; Humans; Indoles; Influenza A virus; Influenza, Human; Mice; NF-kappa B; Orthomyxoviridae Infections; Quinolines; Signal Transduction	2017
Development of Novel Anti-influenza Thiazolides with Relatively Broad-Spectrum Antiviral Potentials. Antimicrobial agents and chemotherapy, 2020, 06-23, Volume: 64, Issue:7 Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza, Human; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Zanamivir	2020
In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses. Viruses, 2020, 10-08, Volume: 12, Issue:10 Topics: Acids, Carbocyclic; Amides; Animals; Antiviral Agents; Cell Line; Dibenzothiepins; Dogs; Drug Combinations; Drug Resistance, Viral; Drug Synergism; Guanidines; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Morpholines; Neuraminidase; Nucleic Acid Synthesis Inhibitors; Orthomyxoviridae Infections; Oseltamivir; Pyrazines; Pyridones; Ribavirin; Triazines; Viral Proteins; Virus Replication; Zanamivir	2020
A universal dual mechanism immunotherapy for the treatment of influenza virus infections. Nature communications, 2020, 11-05, Volume: 11, Issue:1 Topics: 2,4-Dinitrophenol; Administration, Intranasal; Animals; Antibodies; Antiviral Agents; Cell Line; Cytotoxicity, Immunologic; Drug Delivery Systems; Humans; Immunotherapy; Influenza A virus; Influenza B virus; Infusions, Parenteral; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Protein Binding; Treatment Outcome; Virus Release; Zanamivir	2020
Design of Neuraminidase-Targeted Imaging and Therapeutic Agents for the Diagnosis and Treatment of Influenza Virus Infections. Bioconjugate chemistry, 2021, 08-18, Volume: 32, Issue:8 Topics: Animals; Enzyme Inhibitors; HEK293 Cells; Humans; Influenza A virus; Influenza, Human; Mice; Neuraminidase; Optical Imaging; Orthomyxoviridae Infections; Viral Proteins; Zanamivir	2021
Mycophenolic mofetil, an alternative antiviral and immunomodulator for the highly pathogenic avian influenza H5N1 virus infection. Biochemical and biophysical research communications, 2017, 12-09, Volume: 494, Issue:1-2 Topics: Animals; Antiviral Agents; Chemokine CXCL10; Chick Embryo; Dogs; Female; Gene Expression Regulation; Host-Pathogen Interactions; Immunologic Factors; IMP Dehydrogenase; Influenza A Virus, H5N1 Subtype; Interferon-beta; Interleukin-1beta; Interleukin-6; Lung; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Mycophenolic Acid; Orthomyxoviridae Infections; Oseltamivir; RNA, Viral; Survival Analysis; Virus Replication; Zanamivir	2017
Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus. The Journal of infectious diseases, 2018, 03-05, Volume: 217, Issue:6 Topics: Amides; Animals; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Female; Guanidines; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Lung; Mice; Mice, Inbred BALB C; Mice, Nude; Neuraminidase; Nucleic Acid Synthesis Inhibitors; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Pyrazines; Sialic Acids; Zanamivir	2018
Efficacy of laninamivir octanoate in mice with advanced inflammation stage caused by infection of highly lethal influenza virus. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2019, Volume: 25, Issue:8 Topics: Animals; Antiviral Agents; Cell Line; Dogs; Enzyme Inhibitors; Female; Guanidines; Inflammation; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2019
Permeability enhancers dramatically increase zanamivir absolute bioavailability in rats: implications for an orally bioavailable influenza treatment. PloS one, 2013, Volume: 8, Issue:4 Topics: Absorption; Administration, Oral; Animals; Biological Availability; Biological Transport; Caco-2 Cells; Cell Membrane Permeability; Enzyme Inhibitors; Humans; Influenza, Human; Male; Neuraminidase; Orthomyxoviridae Infections; Rats; Rats, Sprague-Dawley; Time Factors; Zanamivir	2013
Zanamivir conjugated to poly-L-glutamine is much more active against influenza viruses in mice and ferrets than the drug itself. Pharmaceutical research, 2014, Volume: 31, Issue:2 Topics: Animals; Antiviral Agents; Ferrets; Glutamine; Influenza A virus; Male; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Structure-Activity Relationship; Zanamivir	2014
Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses. Antiviral research, 2014, Volume: 105 Topics: Animals; Antiviral Agents; Body Weight; Disease Models, Animal; Drug Therapy, Combination; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Lung; Mice, Inbred C57BL; Orthomyxoviridae Infections; Oseltamivir; Survival Analysis; Treatment Outcome; Viral Load; Zanamivir	2014
A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses. The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:8 Topics: Animals; Antiviral Agents; Dogs; Drug Combinations; Drug Resistance, Viral; Enzyme Inhibitors; Female; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Zanamivir	2014
Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes. Antiviral research, 2015, Volume: 117 Topics: Acids, Carbocyclic; Adamantane; Amino Acid Substitution; Animals; Antiviral Agents; Base Sequence; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Genotype; Guanidines; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H1N2 Subtype; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Mutation, Missense; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Phenotype; Phylogeny; Swine; Swine Diseases; Time Factors; United States; Viral Proteins; Zanamivir	2015
Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection. Antiviral research, 2015, Volume: 120 Topics: Administration, Inhalation; Animals; Antiviral Agents; Disease Models, Animal; Drug Carriers; Ferrets; Guanidines; Orthomyxoviridae Infections; Placebos; Powders; Pyrans; Sialic Acids; Zanamivir	2015
Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability. Journal of pharmaceutical sciences, 2015, Volume: 104, Issue:9 Topics: Administration, Oral; Amidines; Animals; Antiviral Agents; Biological Availability; Cell Line; Dogs; Enzyme Inhibitors; Guanidines; Hydroxylamines; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Neuraminidase; Orthomyxoviridae Infections; Prodrugs; Rats; Rats, Wistar; Zanamivir	2015
The Intranasal Application of Zanamivir and Carrageenan Is Synergistically Active against Influenza A Virus in the Murine Model. PloS one, 2015, Volume: 10, Issue:6 Topics: Administration, Intranasal; Animals; Antiviral Agents; Carrageenan; Disease Models, Animal; Dogs; Humans; Influenza A virus; Influenza A Virus, H7N7 Subtype; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Mice; Orthomyxoviridae Infections; Treatment Outcome; Zanamivir	2015
Impact of a large deletion in the neuraminidase protein identified in a laninamivir-selected influenza A/Brisbane/10/2007 (H3N2) variant on viral fitness in vitro and in ferrets. Influenza and other respiratory viruses, 2016, Volume: 10, Issue:2 Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Ferrets; Gene Deletion; Genetic Fitness; Guanidines; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Mutation; Neuraminidase; Orthomyxoviridae Infections; Pyrans; RNA, Viral; Sialic Acids; Virus Replication; Zanamivir	2016
Within-Host Models of High and Low Pathogenic Influenza Virus Infections: The Role of Macrophages. PloS one, 2016, Volume: 11, Issue:2 Topics: Animals; Anti-Inflammatory Agents; Antibodies, Viral; Antiviral Agents; B-Lymphocytes; Cell Death; Epithelial Cells; Host-Pathogen Interactions; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Macrophage Activation; Macrophages; Mice; Mice, Inbred BALB C; Models, Immunological; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Viral Load; Virulence; Zanamivir	2016
Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses. Journal of visualized experiments : JoVE, 2017, 01-20, Issue:119 Topics: Animals; Antiviral Agents; Disease Models, Animal; Humans; Influenza A virus; Neutrophils; Orthomyxoviridae Infections; Zanamivir; Zebrafish	2017
Selection of multi-drug resistant influenza A and B viruses under zanamivir pressure and their replication fitness in ferrets. Antiviral therapy, 2018, Volume: 23, Issue:4 Topics: Animals; Antiviral Agents; Disease Susceptibility; Drug Resistance, Viral; Ferrets; Genetic Fitness; Influenza A virus; Influenza B virus; Microbial Sensitivity Tests; Mutation; Orthomyxoviridae Infections; Recombination, Genetic; RNA, Viral; Sequence Analysis, DNA; Virus Replication; Zanamivir	2018
Insights into inflammation and influenza. The New England journal of medicine, 2008, Oct-09, Volume: 359, Issue:15 Topics: Animals; Antiviral Agents; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Humans; Immunologic Factors; Influenza A Virus, H5N1 Subtype; Influenza, Human; Mesalamine; Mice; Orthomyxoviridae Infections; Pyrazoles; Sulfonamides; Zanamivir	2008
Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. Journal of virology, 2009, Volume: 83, Issue:20 Topics: Animals; Antiviral Agents; Asia, Southeastern; Australasia; Cell Line; Drug Resistance, Viral; Female; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Zanamivir	2009
[Inquired of the President of the.Robert Koch Institute. How dangerous is Mexican influenza?]. MMW Fortschritte der Medizin, 2009, May-07, Volume: 151, Issue:19 Topics: Animals; Antiviral Agents; Disease Outbreaks; Enzyme Inhibitors; Germany; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mexico; Orthomyxoviridae Infections; Oseltamivir; Swine; World Health Organization; Zanamivir	2009
Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS pathogens, 2010, Feb-26, Volume: 6, Issue:2 Topics: Animals; Antiviral Agents; Female; Guanidines; Influenza A Virus, H5N1 Subtype; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Prodrugs; Pyrans; Sialic Acids; Zanamivir	2010
Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets. PLoS pathogens, 2010, May-27, Volume: 6, Issue:5 Topics: Animals; Antiviral Agents; Cell Line; Crystallography; Disease Models, Animal; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Ferrets; Humans; Influenza A Virus, H5N1 Subtype; Kidney; Male; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Protein Structure, Tertiary; Recombinant Proteins; Zanamivir	2010
Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. Antiviral research, 2010, Volume: 87, Issue:3 Topics: Amino Acid Substitution; Animals; Antiviral Agents; Disease Models, Animal; DNA Mutational Analysis; Drug Resistance, Viral; Female; Ferrets; Humans; Influenza A Virus, H5N1 Subtype; Inhibitory Concentration 50; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Viral Proteins; Zanamivir	2010
Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype. Journal of virology, 2010, Volume: 84, Issue:19 Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Birds; Catalytic Domain; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza in Birds; Influenza, Human; Models, Molecular; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Protein Conformation; Species Specificity; Swine; Swine Diseases; Viral Proteins; Zanamivir	2010
Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. Journal of virology, 2010, Volume: 84, Issue:21 Topics: Animals; Disease Models, Animal; Drug Resistance, Viral; Ferrets; Guinea Pigs; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Orthomyxoviridae Infections; Oseltamivir; Zanamivir	2010
Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus. Journal of virology, 2011, Volume: 85, Issue:10 Topics: Amino Acid Substitution; Animals; Antiviral Agents; Asparagine; Disease Models, Animal; Drug Resistance, Viral; Female; Ferrets; Influenza A Virus, H5N1 Subtype; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Point Mutation; Rodent Diseases; Serine; Survival Analysis; Treatment Outcome; Viral Proteins; Virulence; Virulence Factors; Virus Replication; Zanamivir	2011
Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008. Medical microbiology and immunology, 2012, Volume: 201, Issue:1 Topics: Animals; Antiviral Agents; Cell Line; Drug Resistance, Viral; Enzyme Inhibitors; Germany; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H1N2 Subtype; Influenza A Virus, H3N2 Subtype; Microbial Sensitivity Tests; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Swine; Swine Diseases; Zanamivir	2012
High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2012, Volume: 18, Issue:1 Topics: Administration, Intranasal; Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Female; Guanidines; Influenza A virus; Inhibitory Concentration 50; Lung; Mice; Mice, Inbred BALB C; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Viral Load; Zanamivir	2012
Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:3 Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Drug Resistance, Viral; Ferrets; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Male; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pandemics; Reverse Genetics; Viral Proteins; Virus Replication; Zanamivir	2012
Laninamivir octanoate and artificial surfactant combination therapy significantly increases survival of mice infected with lethal influenza H1N1 Virus. PloS one, 2012, Volume: 7, Issue:8 Topics: Animals; Body Weight; Carbon Dioxide; Chemokines; Dogs; Drug Therapy, Combination; Female; Guanidines; Influenza A Virus, H1N1 Subtype; Lung; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Organ Size; Orthomyxoviridae Infections; Oxygen; Pressure; Pulmonary Surfactant-Associated Protein D; Pulmonary Surfactants; Pyrans; Sialic Acids; Survival Analysis; Viral Load; Zanamivir	2012
A chemically programmed antibody is a long-lasting and potent inhibitor of influenza neuraminidase. Chembiochem : a European journal of chemical biology, 2012, Oct-15, Volume: 13, Issue:15 Topics: Animals; Antibodies, Monoclonal; Antiviral Agents; Click Chemistry; Fructose-Bisphosphate Aldolase; Humans; Immunoconjugates; Influenza A virus; Influenza, Human; Mice; Models, Molecular; Neuraminidase; Orthomyxoviridae Infections; Zanamivir	2012
Polymer-attached zanamivir inhibits synergistically both early and late stages of influenza virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2012, Dec-11, Volume: 109, Issue:50 Topics: Animals; Antiviral Agents; Dogs; Drug Synergism; Endocytosis; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Microscopy, Electron, Transmission; Neuraminidase; Orthomyxoviridae Infections; Peptides; Zanamivir	2012
Pandemic 2009 H1N1 influenza A virus carrying a Q136K mutation in the neuraminidase gene is resistant to zanamivir but exhibits reduced fitness in the guinea pig transmission model. Journal of virology, 2013, Volume: 87, Issue:3 Topics: Amino Acid Substitution; Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Viral; Guinea Pigs; Influenza A Virus, H1N1 Subtype; Molecular Sequence Data; Mutant Proteins; Mutation, Missense; Neuraminidase; Orthomyxoviridae Infections; RNA, Viral; Sequence Analysis, DNA; Viral Proteins; Virulence; Virulence Factors; Zanamivir	2013
Semi-quantitative detection of viral RNA in influenza A virus-infected mice for evaluation of antiviral compounds. Antiviral research, 2003, Volume: 58, Issue:1 Topics: Animals; Antibodies, Viral; Antiviral Agents; Disease Models, Animal; Female; Guanidines; Influenza A virus; Lung; Mice; Mice, Inbred BALB C; Nasopharynx; Orthomyxoviridae Infections; Pyrans; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sialic Acids; Trachea; Zanamivir	2003
Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model. Pediatric pulmonology, 2003, Volume: 36, Issue:4 Topics: Acetamides; Animals; Antiviral Agents; Disease Models, Animal; Drug Therapy, Combination; Glucocorticoids; Guanidines; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Rats; Sialic Acids; Sigmodontinae; Triamcinolone Acetonide; Zanamivir	2003
Assessment of development of resistance to antivirals in the ferret model of influenza virus infection. The Journal of infectious diseases, 2003, Nov-01, Volume: 188, Issue:9 Topics: Amantadine; Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Viral; Ferrets; Guanidines; Hemagglutination Inhibition Tests; Influenza A virus; Male; Orthomyxoviridae Infections; Point Mutation; Pyrans; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sequence Analysis, DNA; Sialic Acids; Zanamivir	2003
Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives. Chemical & pharmaceutical bulletin, 2003, Volume: 51, Issue:12 Topics: Administration, Intranasal; Animals; Antiviral Agents; Cell Line; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Guanidines; Influenza A virus; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Pyrans; Sialic Acids; Zanamivir	2003
Influenza infection of the embryonated hen's egg/an alternative model for in vivo evaluation of antiviral compounds. Arzneimittel-Forschung, 2004, Volume: 54, Issue:2 Topics: Amantadine; Animals; Antiviral Agents; Chick Embryo; Drug Evaluation, Preclinical; Guanidines; Influenza A virus; Orthomyxoviridae Infections; Pyrans; Rimantadine; Sialic Acids; Survival Analysis; Zanamivir	2004
Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen. Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:12 Topics: Animals; Antiviral Agents; Cell Line; Chromatography, Gel; Cytopathogenic Effect, Viral; Dogs; Enzyme Inhibitors; Guanidines; Indicators and Reagents; Kinetics; Lung; Male; Mice; Microscopy, Electron; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Pyrans; Rats; Rats, Sprague-Dawley; Sialic Acids; Structure-Activity Relationship; Viral Plaque Assay; Virus Replication; Zanamivir	2004
Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza. Journal of medicinal chemistry, 2005, Apr-21, Volume: 48, Issue:8 Topics: Animals; Antiviral Agents; Cell Line; Crystallization; Dimerization; Guanidines; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza B virus; Lung; Male; Membranes, Artificial; Mice; Models, Molecular; Molecular Weight; Neuraminidase; Orthomyxoviridae Infections; Pyrans; Rats; Rats, Sprague-Dawley; Sialic Acids; Stereoisomerism; Viral Plaque Assay; Zanamivir	2005
Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo. Bioorganic & medicinal chemistry, 2005, Jun-02, Volume: 13, Issue:12 Topics: Acetamides; Acids, Carbocyclic; Administration, Intranasal; Administration, Oral; Animals; Antiviral Agents; Cyclopentanes; Dose-Response Relationship, Drug; Guanidines; Mice; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Structure-Activity Relationship; Survival Rate; Treatment Outcome; Zanamivir	2005
Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. The Journal of infectious diseases, 2005, Aug-15, Volume: 192, Issue:4 Topics: Acetamides; Animals; Antiviral Agents; Brain; Cell Line; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Guanidines; Influenza A virus; Inhibitory Concentration 50; Lung; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Virulence; Virus Replication; Zanamivir	2005
Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:10 Topics: Acetamides; Amino Acid Substitution; Animals; Cell Line; Coculture Techniques; Disease Models, Animal; Drug Resistance, Multiple; Drug Resistance, Viral; Drug Tolerance; Enzyme Inhibitors; Enzyme Stability; Female; Ferrets; Genetic Variation; Guanidines; Kinetics; Mutagenesis, Site-Directed; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Recombination, Genetic; Sialic Acids; Temperature; Virus Replication; Zanamivir	2005
Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:10 Topics: Amantadine; Animals; Antiviral Agents; Guanidines; Influenza A virus; Influenza B virus; Mice; Neuraminidase; Orthomyxoviridae Infections; Pyrans; Ribavirin; Sialic Acids; Virus Replication; Zanamivir	1994
GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrobial agents and chemotherapy, 1995, Volume: 39, Issue:11 Topics: Administration, Intranasal; Animals; Antiviral Agents; Ferrets; Guanidines; Influenza A virus; Influenza B virus; Orthomyxoviridae Infections; Pyrans; Sialic Acids; Zanamivir	1995
Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:3 Topics: Acetamides; Administration, Oral; Amines; Animals; Antiviral Agents; Disease Models, Animal; Female; Ferrets; Guanidines; Influenza A virus; Influenza B virus; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Prodrugs; Pyrans; Rats; Rats, Sprague-Dawley; Sialic Acids; Virus Replication; Zanamivir	1998
The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en. Virology, 1998, Jun-20, Volume: 246, Issue:1 Topics: Animals; Antiviral Agents; Cell Line; DNA Mutational Analysis; Dogs; Drug Resistance, Microbial; Female; Ferrets; Genes, Viral; Guanidines; Hemagglutinin Glycoproteins, Influenza Virus; Mice; Mice, Inbred C57BL; Mutation; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Pyrans; Sialic Acids; Viral Plaque Assay; Viral Structural Proteins; Virus Replication; Zanamivir	1998
Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. The Journal of infectious diseases, 1998, Volume: 178, Issue:5 Topics: Amino Acid Substitution; Animals; Antiviral Agents; Bone Marrow Transplantation; Cell Line; Chlorocebus aethiops; Dogs; Drug Resistance, Microbial; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Ferrets; Guanidines; Hemagglutination Inhibition Tests; Humans; Immunosuppression Therapy; Infant; Influenza B virus; Influenza, Human; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neuraminidase; Orthomyxoviridae Infections; Pyrans; Receptors, Virus; RNA, Viral; Sialic Acids; Vero Cells; Zanamivir	1998
Chemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tract. Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:11 Topics: Administration, Intranasal; Animals; Antiviral Agents; Autoradiography; Body Weight; Female; Ferrets; Guanidines; Influenza A virus; Lung; Mice; Orthomyxoviridae Infections; Pyrans; Respiratory System; Sialic Acids; Zanamivir	1999
Relenza. Current biology : CB, 1999, Nov-04, Volume: 9, Issue:21 Topics: Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Pyrans; Sialic Acids; Zanamivir	1999
Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:4 Topics: Acetamides; Acids, Carbocyclic; Administration, Intranasal; Administration, Oral; Animals; Antiviral Agents; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Species Specificity; Survival Analysis; Time Factors; Zanamivir	2001
Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:4 Topics: Administration, Intranasal; Animals; Antiviral Agents; Brain; Cell Line; Dogs; Enzyme Inhibitors; Female; Genes, Viral; Guanidines; Influenza A virus; Influenza A Virus, H5N1 Subtype; Kinetics; Lung; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Neuraminidase; Orthomyxoviridae Infections; Pyrans; Sialic Acids; Species Specificity; Virus Replication; Zanamivir	2001
Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:10 Topics: Acetamides; Acids, Carbocyclic; Animals; Antiviral Agents; Body Weight; Brain; Cyclopentanes; Disease Models, Animal; Dogs; Female; Guanidines; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H9N2 Subtype; Lung; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Virus Replication; Zanamivir	2001